

Fastsættelse af kvalitetskriterier for

Irgalube (353)

CAS nr. 268567-32-4

Vandkvalitetskriterium VKK $_{ferskvand}$ 72 $\mu g/l$ Vandkvalitetskriterium VKK $_{saltvand}$ 7,2 $\mu g/l$ Korttidsvandkvalitetskriterium KVKK $_{ferskvand}$ 3800 $\mu g/l$

1

31-05-2019

Indhold

| F(| ORORD | | 3 |
|----|----------------------------------|---|----------------------|
| E | NGLISH | I SUMMARY AND CONCLUSIONS | 4 |
| 1 | INDL | EDNING | 5 |
| 2 | FYSI | SK KEMISKE EGENSKABER | 6 |
| 3 | SKÆ | BNE I MILJØET | 8 |
| | 3.2 I 3.3 N | NEDBRYDELIGHED BIOAKKUMULERING NATURLIG FOREKOMST TIGHEDSDATA | 8 8 8 9 |
| | 4.2 (4.3 (| GIFTIGHED OVER FOR VANDLEVENDE ORGANISMER GIFTIGHED OVER FOR SEDIMENTLEVENDE ORGANISMER GIFTIGHED OVER FOR PATTEDYR OG FUGLE GIFTIGHED OVER FOR MENNESKER | 9 9 9 10 |
| 5 | AND | RE EFFEKTER | 11 |
| 6 | UDL | EDNING AF VANDKVALITETSKRITERIUM | 12 |
| | 6.2 H 6.3 H 6.4 H 6.5 H | VANDKVALITETSKRITERIUM (VKK) KORTTIDSVANDKVALITETSKRITERIUM (KVKK) KVALITETSKRITERIUM FOR SEDIMENT (SKK) KVALITETSKRITERIUM FOR BIOTA (BKK) KVALITETSKRITERIUM FOR HUMAN KONSUM AF VANDLEVENDE ORGANISMER (HKK) | 12 12 12 12 |
| 7 | KON | KLUSION | 13 |
| 8 | REFI | ERENCER | 14 |
| 9 | BILA | G A. KVALITETSEVALUERING AF DATA | 15 |
| 10 | BILA | G B. (Q)SAR PROFIL FRA DANISH (Q)SAR DATABASE | 28 |

Forord

Et kvalitetskriterium i vandmiljøet er det højeste koncentrationsniveau, ved hvilket der skønnes, at der ikke

vil forekomme uacceptable negative effekter på vandøkosystemer.

Miljøstyrelsen (MST) udarbejder kvalitetskriterier for kemikalier i vandsøjlen (vandkvalitetskriterium), i

sediment og i dyr og planter (biota).

Miljøstyrelsen bruger kvalitetskriterierne som det faglige grundlag til at kunne fastsætte miljøkvalitetskrav,

hvorved der forstås den endelige koncentration af et bestemt forurenende stof i vand, sediment eller biota,

som ikke må overskrides af hensyn til beskyttelsen af miljøet og menneskers sundhed.

Metodikken, der anvendes til udarbejdelse af miljøkvalitetskrav er harmoniseret i EU og baserer sig på

vandrammedirektivet (EU 2000), EU's vejledning til fastsættelse af kvalitetskriterier i vandmiljøet (EU 2011) og Miljøstyrelsens vejledning til fastsættelse af vandkvalitetskriterier (Miljøstyrelsen 2004). Metodikken er

endvidere i overensstemmelse med EU's vejledning til risikovurdering under REACH forordningen (EU 2008).

Den sidste litteratursøgning er foretaget den 28-11-2018.

Hans Sanderson, Institut for Miljøvidenskab, Aarhus Universitet

Faglig kvalitetssikring: John Jensen, Institut for Bioscience, Aarhus Universitet

Kvalitetssikring, DCE: Susanne Boutrup

3

English Summary and conclusions

There is a REACH registration for the compound Irgalube which contains data for the compound. It was not possible to derive relevant EQS data from other literature sources or databases. Hence, the (Q)SAR profile from the Danish (Q)SAR is also attached. It is not biodegradable within 28 days in water. There is no data on degradability in sediment and soil. An analysis of BDF (OECD 305) found the BCF to be 2 to 10 L/kg (ww). The total tonnage in Denmark in 2016 was 33.1 tons and 100-1000 tons in the EU. The EQS values are the following:

| AA-EQS _{freshwater} = | 72 μg/L |
|--------------------------------|-----------|
| AA-EQSsaltwater = | 7.2 μg/L |
| MAC = | 3800 μg/L |

1 Indledning

Identiteten af Irgalube fremgår af tabel 1.1. Der findes flere forskellige formuleringer af Irgalube. CAS nummer 268567-32-4 dækker over Irgalube 353. Irgalube er et olie produkt, der benyttes som smøreprodukt i gear og turbiner samt som hydraulisk væske. Det kan desuden anvendes i fremstillingen af pesticider, Cheminova fik i 2014 et tillæg til miljøgodkendelse af beslægtede Irgalube 62 og 63. I 2016 benyttedes 33,1 tons Irgalube i Danmark (SPIN database). Total tonnage i EU er mellem 100-1000 tons/år. Dette datablad dækker kun Irgalube 353 - i det følgende i databladet benævnt Irgalube.

Tabel 1.1. Identitet

| IUPAC navn | Propanoic acid, 3-((bis(2-methylpropoxy)phosphinothioyl)thio)-2-methyl- |
|----------------|---|
| Strukturformel | H ₃ C O-P=S CH ₃ H ₃ C CH ₃ |
| CAS nr. | 268567-32-4 |
| EINECS nr. | 434-070-2 |
| Kemisk formel | C ₁₂ H ₂₅ O ₄ PS ₂ |
| SMILES | C(CSP(=S)(OCC(C)C)OCC(C)C)(C)C(=O)O |

2 Fysisk kemiske egenskaber

De fysisk kemiske egenskaber for Irgalube fremgår af tabel 2.1. Stoffet er mindre vandopløseligt.

Tabel 2.1. Fysisk kemiske egenskaber for Irgalube

| Parameter | Værdi | Reference |
|--|--|-----------------------------------|
| Molekylevægt, M _w (g·mol⁻¹) | 328,42 | EPI Suite |
| Smeltepunkt, T _m (°C) | Flydende indtil -45 | EU REACH Registreringen (2018) |
| Kogepunkt, T _b (°C) | >175 | EU REACH Registreringen (2018) |
| Damptryk, P _v (Pa) (20 °C) | 6,5E-5 | EU REACH Registreringen (2018) |
| Henry's konstant, H (pa·m³·mol⁻¹) | 4,54E-9 | EPI Suite |
| Vandopløselighed, S _w (mg·L ⁻¹) | 7,8 ¹ | EU REACH Registreringen (2018) |
| Dissociationskonstant, pK _a | 4,27 (udenfor normal pH 5-9) ved 25C – kan ikke dissocieres ved relevant forhold. | EU REACH Registreringen (2018) |

¹ Ved 20°C

6

| Octanol/vand | 3,9 | EU REACH |
|--|---------|-----------------------|
| fordelingskoefficient, log K _{ow} | | Registreringen (2018) |
| | | |
| K _{oc} | 213-504 | EPI Suite |
| (L·kg-1) | | |

^{#1}Nedbrydes inden kogepunktet

3 Skæbne i miljøet

3.1 Nedbrydelighed

Irgalube har en hydrolyse halveringstid på 11 dage ved pH 4 og 25C, ved lavere temperaturer og højere pH er stoffets hydrolyse halveringstid over 1 år. Stoffet er ikke bionedbrydeligt indenfor 28 dage i vand. Der er ingen data på nedbrydelighed i jord og sediment (EU REACH registreringen, 2018). Ud fra (Q)SAR data er stoffet ikke hurtigt bionedbrydeligt (bilag B).

3.2 Bioakkumulering

Stoffet er testet på *Cyprinus carpio* (japansk karpe) ved to forskellige koncentrationer i henhold til OECD 305, BCF er fundet til mellem 2 og 10 L/kg (ww). Det konkluderes at stoffet ikke akkumuleres i karpe (EU REACH Registreringen, 2018). (Q)SAR resultaterne viser en BCF = 3,1 L/kg (ww) og en biotransformationstid i fisk på ca. 2,5 dage (bilag B).

3.3 Naturlig forekomst

Stoffet er ikke naturligt forekommende.

4 Giftighedsdata

4.1 Giftighed over for vandlevende organismer

Der forligger kun få studier af Iraglubes giftighed over for vandlevende organismer. Søgning i SciFinder og google scholar returnered ingen fund på kombinationer af: Irgalube; Irgalube 353; CAS 268567-32-4; toxicity; aquatic toxicity. Ingen relevante andre databaser (fx ecotox mfl.) har giftighedsdata på stoffet. De to eneste datakilder er EU REACH registreringen opdateret i 2018 (EU REACH registreringen, 2018) med målte værdier, samt (Q)SAR værdi for *Daphnia magna*, der er også værdier for fisk og alger men disse er statistisk set mindre robuste og derfor ikke medtaget her. Resultaterne er samlet i tabel 4.1 nedenfor.

Tabel 4.1. Effekt koncentrationer anvendt i fastsættelsen af vandkvalitetskriterium, målte koncentrationer, (EU REACH Registreringen (2018)), samt (Q)SAR værdier.

| Art / test guideline | Effekt konc. | Eksponerings- | Effektmål | CRED |
|--------------------------------------|--------------------------|---------------|--------------------|-------|
| _ | (mg/L) | tid | | score |
| Zebrafisk (Danio rerio) (OECD 203) | 38 (EC ₅₀) | 96 t | Overlevelse | 1 |
| Daphnia magna (OECD 202) | 53 (EC ₅₀) | 48 t | Overlevelse | 1 |
| Daphnia magna (OECD 211) | 3,6 (NOEC) | 21 d | Reproduktion/vækst | 1 |
| Algae (Desmodesmus subspicatus) OECD | 66 (EC ₁₀) | 72 t | Vækstrate | 1 |
| 201) | | | | |
| Algae (Desmodesmus subspicatus) OECD | >100 (EC ₅₀) | 72 t | Vækstrate | 1 |
| 201) | | | | |
| Daphnia magna (QSAR) ² | 1,2 (EC ₅₀) | 48 | Overlevelse | 2 |

4.2 Giftighed over for sedimentlevende organismer

Ingen data (EU REACH Registreringen, 2018).

4.3 Giftighed over for pattedyr og fugle

Der er få giftighedsdata for pattedyr og fugle, primært rotteforsøg med følgende resultater. Akut LD₅₀ for rotter er >2000 mg/kg lgv/d og NOAEL_{rotter 92-d} = 125 mg/kg lgv/d (EU REACH Registreringen, 2018). Der er ikke fundet sub-letal toksicitet ved pattedyr og fugle i de forsøg dossieret præsenterer.

² Se bilag B QSAR data.

(Q)SAR analyserne støtter generelt de negative eksperimentelle fund med hensyn til mutagenicitet. Der er dog også enkelte positive fund som er fremhævet i gult i bilag B og listet nedenfor:

- Estrogen Receptor α Binding, Full training set (Human *in vitro*)
- Ashby Structural Alerts
- Syrian Hamster Embryo (SHE) Cell Transformation
- Sex-Linked Recessive Lethal (SLRL) Test in Drosophila m
- Dominant Lethal Mutations in Rodents
- Comet Assay in Mouse
- Liver Specific Cancer in Rat or Mouse

4.4 Giftighed over for mennesker

Irgalube har følgende Derived No Effect Levels (DNELs) for den generelle befolkning på baggrund af rotteforsøg (EU REACH Registreringen, 2018): Inhalation DNEL = 1,09 mg/m³; Oral og dermal DNEL = 0,6 mg/kg lgv/d.

5 Andre effekter

H317: Kan forårsage hudallergi

H318: Skadeligt for øjne

6 Udledning af vandkvalitetskriterium

6.1 Vandkvalitetskriterium (VKK)

Af tabel 4.1 fremgår det, at der findes tre akutte datasæt for tre trofiske niveauer, samt et kronisk datasæt for *Daphnia magna*. *D. magna* er ikke den mest følsomme art i akut-testsættet, men da EC₅₀ for *D. magna* (53 mg/l) ikke er væsentligt større end EC₅₀ for Zebrafisk (*D. rerio*) (38 mg/L) (faktor 1,4) er toksiciteten over for *D. magna* på linje med toksiciteten for *D. rerio*. I henhold til Guidance Document No. 27 (EU 2011) (TGD#27) anvendes derfor en usikkerhedsfaktor på 50 på det kroniske resultat for *D. magna*. Vandkvalitetskriteriet for saltvand findes ved yderligere en ekstrapolationsfaktor på 10:

PNEC/VKK_{ferskvand} = 3,6 mg/L/50 = 0,072 mg/L = $\frac{72 \mu g/L}{L}$

PNEC/VKK_{saltvand} = PNEC/VKK_{ferskvand} $/10 = 0,0072 \text{ mg/L} = \frac{7.2 \text{ } \mu\text{g/L}}{10 \text{ }}$

6.2 Korttidsvandkvalitetskriterium (KVKK)

For korttidskriteriet KVKK for både fersk- og saltvand benyttes data for akut effekt på fisk på 38 mg/L som data udgangspunkt. Da standardafvigelsen på de Log10-konverterede toksicitetsdata er mindre end 0,5 anvendes ifølge TGD#27 en ekstrapolationsfaktor på 10 så KVKK for både fersk- og saltvand = 38 mg/L/10 = 3.8 mg/L = 3.800 µg/L.

6.3 Kvalitetskriterium for sediment (SKK)

Log K_{oc} er 2,7 (og dermed mindre end 3) og det er derfor ifølge TGD#27 ikke relevant, at fastsætte et SKK.

6.4 Kvalitetskriterium for biota (BKK)

Irgalube har en Log K_{ow} på 3,9 (Tab 2.1), men en BCF værdi på 2-10 L/kg (ww) og det er derfor ikke nødvendigt at fastsætte et biota kvalitetskriterium, der beskytter mod sekundær forgiftning ifølge TGD#27 (Tab 2.4.3.1).

6.5 Kvalitetskriterium for human konsum af vandlevende organismer (HKK)

Der er ingen kriterier (fx CMR) eller faresætninger, der indikerer mistanke om høj toksicitet over for mennesker, og det er derfor ikke relevant at fastsætte et kriterium af hensyn til human konsumption.

7 Konklusion

Der er fundet følgende miljøkvalitetskriterier for Irgalube baseret på data fra REACH registreringsdossieret (EU, 2018) og TGD#27 metoder:

 $VKK_{ferskvand} = 72 \mu g/L$

 $VKK_{saltvand} = 7.2 \mu g/L$

 $KVKK_{ferskvand}$ = 3800 μ g/L

8 Referencer

EU 2000. Europa-Parlamentets og Rådets Direktiv 2000/60/EF om fastsættelse af en ramme for fællesskabets vandpolitiske foranstaltninger af 23. oktober 2000.

EU 2008. ECHA: Guidance on information requirements and chemical safety assessment Chapter R.10: Characterisation of dose [concentration]-response for environment (https://echa.europa.eu/documents/10162/13632/information_requirements_r10_en.pdf/bb902be7-a503-4ab7-9036-d866b8ddce69)

EU 2011. Common Implementation Strategy for the Water Framework Directive (2000/60/EC). Guidance Document No. 27. Technical Guidance Document for Deriving Environmental Quality Standards.

EU 2018. Irgalube ECHA registration: https://echa.europa.eu/registration-dossier/-/registered-dossier/5213/7/1

Miljøstyrelsen 2004. Principper for fastsættelse af vandkvalitetskriterier for stoffer i overfladevand. Vejledning fra Miljøstyrelsen nr. 4, 2004.

Miljøstyrelsen 2014. J. Nr. MST-1270-01158. Tillæg til miljøgodkendelse for Cheminova:

https://mst.dk/.../20140331 cheminova milj godkendelse-fremstilling-irgalube 62 o...

9 Bilag A. Kvalitetsevaluering af data

De relativt få studier på stoffet findes i EU registreringsdossieret (EU,2018). De anvendte data har alle Klimish 1 scores (acceptable uden restriktioner) og opdateret i 2018. Vedlagt er evalueringsrapporten for den kritiske kroniske test med *Daphnia magna*. Der er kun adgang til robust study summary i dossieret med begrænsede detaljer hvorfor en dybdegående analyse ikke er mulig. Er anført som et GLP studie derfor CRED 1 som anført i dossieret. På grund af de få tilgængelige data er derfor også vedlagt Irgalubes profil baseret på den danske (Q)SAR database.

| Evaluated study (full reference): | Long term toxicity to aquatic invertebrates. REACH study report from REACH dossier |
|-----------------------------------|--|
| Test substance: | Irgalube (CAS#268567-32-4) |
| Evaluated test: | Long term exposure of <i>D magna</i> to Irgalube |
| Evaluated test species: | Waterflea (Daphnia magna) |
| Evaluated test endpoint(s): | Reproduction |
| Evaluator (institution): | Hans Sanderson, Department of Environmental Science, Aarhus University |

Remark: Relevance of a study mainly depends on the scope of the assessment / the regulatory framework, for which the study is evaluated. The following 12 questions should therefore be answered in the context of the overall assessment.

| | Yes | No |
|---|-----|-----|
| Is the tested species relevant for the compartment under evaluation? | Х | |
| Example: An aquatic species should be tested to evaluate risks for the aquatic environment. | | |
| | Yes | No |
| Are the tested organisms relevant for the tested compound? | Х | |
| Example: In case of an ERA for an antibiotic, cyanobacteria should be used as test species instead of algae. | Yes | No |
| Are the reported endpoints appropriate for the regulatory purpose? | X | 140 |
| Example: Acute effects on aquatic organisms are not relevant for the environmental risk assessment of human pharmaceuticals. | Yes | No |
| Are the reported endpoints appropriate for the investigated effects or the mode of action of the test substance? | Х | 110 |
| Explanation: When a risk assessment is performed for a substance, for which information is available on a specific mode of action that is considered relevant for environmental organisms, studies including endpoints assessing this particular mode of action are most appropriate. For instance, if an API is known to affect reproduction of vertebrates, the endpoints of the fish early life stage test may not be appropriate. Instead, fish tests should include endpoints such as vitellgenin levels, secondary sex characteristics, sex ratio and reproduction depending on the specific mode of action of the substance (OECD 2012). | | |
| | Yes | No |
| Is the effect relevant on a population level? | х | |

Explanation: Endpoints of the guideline studies, on which the ERA of human pharmaceuticals is based, are generally population relevant. For non-standard tests, population relevance has to be evaluated on a case by case basis.

| | Yes | No |
|--|-----|----|
| Is the recorded effect statistically significant, biologically relevant and appropriate for the regulatory purpose? | х | |
| Explanation: In the context of environmental risk assessment, a biologically relevant effect is an effect that is important and meaningful for environmental health (EFSA 2011). In a test system with relatively little control variation, minor changes may be statistically significant without necessarily being biologically relevant. To evaluate risks caused by chronic exposure, NOEC or EC_{10} values are used, while EC_{50} values are not appropriate. For the EC_{10} , it has to be evaluated on a case by case basis, if the effect is within biological variation of the control response. To evaluate risks caused by acute exposure (note that this is only relevant for some terrestrial tests with human pharmaceuticals), EC_{50} values are preferred. | V | No |
| | Yes | No |
| Are appropriate life-stages studied? | х | |
| Explanation/example: The tested life stage should be (a) appropriate for the selected test and test design and (b) relevant for the expected effect of the API. For instance, fish early life stages are not appropriate for studying effects on reproduction. | | |
| | Yes | No |
| Are the test conditions appropriate for the tested species and relevant for the assessment? | х | |
| Explanation/example: Test organisms should be tested under appropriate conditions. For instance, freshwater species should be tested in freshwater, and saltwater species in saltwater. If a test with freshwater or saltwater species is required depends on the scope of the assessment. | | • |
| | Yes | No |
| Is the timing and duration of exposure relevant and appropriate for the studied endpoints and species? | x | |
| | | |

Explanation: The required exposure time should be appropriate for the test organism and the studied endpoint. Chronic studies should include sensitive life stages or cover the whole life cycle.

| | Yes | No |
|--|-----|----|
| If recovery is studied, is this relevant for the framework for which the study is evaluated? | | NA |
| Explanation: In most regulatory frameworks (including the environmental risk assessment of human pharmaceuticals), recovery is not relevant (exception: authorisation of plant protection products). | | |
| | Yes | No |
| Is the substance tested representative and relevant for the substance being assessed? | x | |

Explanation: Sufficient information should be provided to allow a clear identification of the test item. A substance may be tested as pure active substance or in a formulation. Tests performed with formulations are relevant for plant protection products, but less relevant within many other regulatory frameworks. Studies with mixtures of different substances are relevant for assessing toxicity of these mixtures, but not for assessing the individual substances contained in the mixture. For salts, the counter ion may influence toxicity. For pro-drugs, the active moiety and, if entering the environment in >10% of the administered does, the pro-drug need to be assessed (EMA/CHMP 2011). Depending on the regulatory framework, effects of transformation products may need to be considered. If the substance causing the effect is not the substance being assessed, expert judgement is needed to decide on how to deal with the results of the study and the resulting risk assessment.

| | Yes | No |
|---|-----|----|
| Is the tested exposure route relevant for the assessment? | х | |
| | | |
| | | |
| | | |

Explanation/example: The exposure route should be appropriate for the assessment. For instance, exposure by injection is generally not appropriate (Harris et al. 2014). For pharmaceuticals, exposure should be continuous. Intermittent exposure is generally not relevant. Exposure duration has to be sufficiently long. However, note that acute tests with some terrestrial organisms are also required in the environmental risk assessment of human pharmaceuticals.

| Assigned relevance of | class | | R1 | |
|-----------------------|-------|--|----|--|
| | | | | |

Reliability of the data

General information

Remark: Before evaluating the test, please check the physico-chemical characteristics of the test substance (what is the solubility, log K_{OW} , pK_{O} , is the compound volatile, does it hydrolyse, photolyse etc.?)

For each question, mark one appropriate answer with x.

| Is a standard method | (e.g. OECD, ISO | , US EPA) or modified standa | ard used? Please specify: |
|----------------------|-----------------|------------------------------|---------------------------|
|----------------------|-----------------|------------------------------|---------------------------|

A standard method is used.

A slightly modified standard method is used.

A substantially modified standard method is used.

| Yes | No |
|-----------|----|
| X OECD211 | |
| | |
| | |
| | Х |
| | |
| | |
| | Х |
| | |
| | |

| Is the | test, including chemical analysis of the test substance where required, performed under GLP ions? | х | |
|---------|---|-----|----|
| Validit | cy criteria: | Yes | No |
| а | Are all validity criteria fulfilled if applicable? | X | NO |
| | Explanation: For standard tests, compliance with the validity criteria of the guideline is crucial for a study to be considered as reliable. Please check the corresponding test guideline where relevant. For non-guideline tests with standard species, validity criteria as described in a guideline for a similar test should be met if applicable. | | |
| | | Yes | No |
| b | Are validity criteria clearly failed? | | х |
| | Explanation: If validity criteria are clearly failed, a test is classified as '3' (not reliable). | | |

Inclusion of appropriate controls:

Explanation: It depends on the test substance and test type which controls should be included; please check the corresponding test guideline where relevant. In addition to the negative control, a solvent control has to be included in all cases where a solvent is used. The concentration of solvent in the solvent control should correspond to the highest solvent concentration used in the test treatments. In some tests, a positive control with a reference substance is required. For standard tests, the corresponding guidelines provide information on how the controls should perform, e.g. with regard to survival, growth or reproduction. For non-standard tests and non-standard test organisms, expert judgement is needed to decide if performance of the controls is acceptable. Performance of the solvent control should preferably not differ significantly from performance of the negative control.

| | | Yes | No |
|---|---|-----|----|
| а | Was a negative control included, and was its performance acceptable? | х | |
| b | Was a positive control included, if required, and was its performance acceptable? | | х |

| С | Was a solvent control included, if a solvent was used, and was its performance acceptable? | | NA |
|---------|--|-------|----|
| Test s | ubstance | Yes | No |
| | test substance clearly identified with name, CAS-number or SMILES code and, where relevant, nation on stereochemistry? | х | |
| | Explanation/example: If the salt of an API was tested, information on the type of salt should be provided. It should be specified if test concentrations relate to free acid / free base or salt. If the test substance is not clearly identified, a test is classified as '3' (not reliable). | | |
| | | Yes | No |
| а | Is the purity of the test substance reported and in an acceptable range (>95%)? | | х |
| b | Is the source of the test substance reported and trustworthy? | Х | |
| If a fo | rmulation is used or if impurities are present: | | |
| а | Can it be excluded that other ingredients in the formulation or impurities exert an effect? | Yes X | No |
| | | | |
| b | Is the amount of test substance in the formulation indicated? | Х | |
| Test o | rganism | | |
| Descr | ption of the test organisms: | | |
| | | Yes | No |
| а | Is the test species clearly identified? | Х | |
| | Explanation: If the test species is not clearly identified, a test is classified as '3' (not reliable). | | |
| | | Vos | No |

| b | For algae: is mean cell density at the test start within an appropriate range? For other test organisms: Is mean body weight/length of the test organism in an appropriate range? | NA | |
|---|--|-----|----|
| | Explanation for 8 b-e: For standard tests, the corresponding guidelines provide information on required range of mean cell densities, age / life stage of the test organisms etc. at the test start. | | |
| | | Yes | No |
| c | Is age/life stage of the organisms at test start reported and in the required range, where appropriate (e.g. not for algae)? | х | |
| d | Is sex of the test organisms reported and is sex ratio appropriate, where relevant (e.g. when evaluating sexual-endocrine effects)? | NA | |
| e | Is the species strain reported where required? | х | |
| а | Are the test organisms from a reliable source? For field collected organisms: is the site of origin well-described? | х | |
| b | Have the organisms been acclimatized to test conditions (e.g. water type, temperature) before the start of exposure, where relevant? For tests with embryonic stages: have the parental organisms been held at appropriate conditions? | х | |
| С | Are the test organisms exempt from previous exposure or any other kind of stressor? | х | |
| | onditions and chemical analysis | | |
| | priateness of the experimental system for the test substance: | Yes | No |
| | type of exposure (e.g. static, semi-static, flow-through) appropriate for the test substance, taking its o-chemical characteristics into account? | х | |

Explanation: Static systems are in most cases only appropriate for short-term tests (exception: water/sediment tests). Where appropriate, guideline requirements should be followed.

| | Yes | No |
|---|-----|----|
| In case that the test substance is a difficult substance as defined in OECD (2000): is the selected test system appropriate for testing of this substance? | х | |
| Explanation: Difficult test substances are substances which are e.g. poorly water soluble, volatile, photo-degradable, hydrolytically unstable, oxidizable, biodegradable, complexing or strongly adsorbing to surfaces of test vessels etc. In order to obtain reliable test results with such substances, test systems generally have to be adapted to take the difficult properties of the substance into account (e.g. by using a closed test system without headspace for volatile substances). For further details, please see OECD (2000). It has to be verified on a case-by-case basis, if the used test system is appropriate for the test substance. | | |
| | Yes | No |
| For ionisable substances: has the test been performed in an appropriate pH-range? | х | |
| Explanation: Relatively small changes in pH can significantly alter the balance between dissociated and non-dissociated forms of some substances. An altered dissociation equilibrium may significantly affect the water solubility and the partition coefficient of the substance and hence, its bioavailability and toxicity. Tests with such substances should therefore be performed at a pH, within the pH range required for maintaining the health of the test organisms, at which the more toxic form of the test substance prevails (as far as possible). For further guidance, see OECD (2000). | | |
| | Yes | No |
| Is the experimental system appropriate for the test organism (e.g. choice of medium / test water or soil, feeding, water or soil characteristics, temperature, light/dark conditions, pH, oxygen content)? Have conditions been stable during the test? | х | |

Explanation: The general requirements of the test species should be considered with regard to the characteristics of the selected test medium etc. Temperature, pH and oxygen content should be stable and within the appropriate range for the organism (where applicable, check the corresponding guideline). If control performance is not good (e.g. high mortality), this may indicate that test conditions were not appropriate. Where applicable, feeding should follow the guideline requirements, and all excess should be removed after feeding to avoid decreased bioavailability of the test substance.

| | Yes | No |
|---|-----|----|
| a For aquatic tests: were exposure concentrations below the limit of water solubility? | х | |
| b For aquatic tests: if a solvent was used, was solvent concentration within the appropriate range (i.e. not higher than 0.01%)? | NA | |
| Is a correct spacing between exposure concentrations applied? | х | |
| Explanation: For standard tests, the corresponding guidelines provide information on the spacing factor. A factor of 3.2 is often recommended. As rule of thumb, the spacing factor should not be >10. | | |
| | Yes | No |
| Is the exposure duration defined and appropriate? | х | |
| Chemical analysis | Yes | No |
| Are chemical analyses performed to verify test substance concentrations over the duration of the study where required? | х | |
| Explanation: If required in the corresponding test guideline, nominal test substance concentrations should be verified by chemical analysis. Non-guideline test should be evaluated based on test guidelines for similar tests where appropriate. | | |
| | Yes | No |
| Is an appropriate analytical method used to measure test substance concentrations? | | NA |

| Are the measured test substance concentrations within the calibration range of the analytical method? | | NA |
|---|-----|----|
| Are samples analysed from a sufficient number of treatments and controls, and from a sufficient number of time intervals? | | NA |
| Explanation: The frequency of chemical analyses should be evaluated based on the requirements of the corresponding test guideline or, for non-guideline studies, on a guideline for a similar test if appropriate. | | |
| | Yes | No |
| Are test substance concentrations sufficiently stable during the course of the exposure ? | | NA |
| Explanation: Please evaluate according to the requirements of the corresponding test guideline or, for non-guideline studies, a test guideline for a similar test where appropriate. | | |
| | Yes | No |
| Is the biomass loading of the organisms in the test system within an appropriate range? | | NA |
| Explanation: For standard tests, the corresponding guidelines provide information on maximum biomass loading. For non-standard tests / non-standard test species, expert knowledge is required to decide if the loading rate is appropriate. | | |
| Statistical design | Yes | No |
| a Is a sufficient number of replicates used for all controls and treatments? | х | |
| b Is a sufficient number of organisms per replicate used for all controls and test concentrations? | х | |
| Explanation for 17 a and b: For standard tests, the guideline requirements should be followed. When a non-guideline study is evaluated, expert judgement is needed to assess if the study design is appropriate to obtain statistically reliable results. | | |
| | Yes | No |
| Are appropriate statistical methods used to derive the effect concentrations? | X | |

Explanation: Generally, a description of the statistical methods is needed to assess the reliability of the test results. For standard tests, the corresponding guideline requirements should be followed. Further guidance is e.g. provided by OECD (2006). When a non-guideline study is evaluated, expert judgment may be needed. ECx values should not be extrapolated considerably beyond the range of tested concentrations.

a Is a concentration-response curve observed? NA NA

Explanation: The requirement for a concentration-response relationship depends on the objective of the study. If a limit test is performed at one (or two) concentration(s) to verify the lack of toxicity and no toxicity is recorded, a concentration-response relationship is obviously not needed to conclude that the LC_{50} or NOEC is above the highest tested concentration. However, if the intention of the study is to demonstrate an effect, reliability of the test results is higher, if (1) a sufficient number of concentrations have been tested and (2) the observed effect is regularly increasing (or regularly decreasing) with increasing test concentration (i.e. the concentration-response relationship is monotonous). Expert knowledge is needed, if an effect is only observed at the highest tested concentration. Expert knowledge is also needed in the case of non-monotonous concentration-response curves (e.g. U-, U- or inverted U-shaped curves). In such cases, the underlying mechanisms of effects and the reproducibility of the results should be considered (Harris et al. 2014).

| | | Yes | No |
|---|---|-----|----|
| b | Is the observed effect statistically significant? | | |
| | Explanation: The significance level and the statistical method used to evaluate the specific effect should be indicated. | Yes | No |
| | officient data available to check the calculation of endpoints and (if applicable) fulfilment of the criteria (e.g. control data, concentration-response curves)? | Х | |

Explanation: If enough data are presented, additional endpoints may be calculated by the assessor if not reported by the author of the study.

| Assigned reliability class | R1 |
|----------------------------|----|
|----------------------------|----|

10 Bilag B. (Q)SAR profil fra Danish (Q)SAR database

(Q)SAR predicted profile

11 Structure (as used for QSAR prediction):

SMILES (used for QSAR prediction): C(=O)(O)C(C)CSP(=S)(OCC(C)C)OCC(C)C

12 ID

| EC Number (pre-registration) | 608-009-7 | EC Number (registration) | 434-070-2 |
|------------------------------|---|---------------------------|-----------|
| Registry Number | 268567-32-4 | PubChem CID | |
| Chemical Name | Propanoic acid, 3-[[bis(2-methylpropoxy)phosphinothioyl]thio]-2-methyl-;3-(Diisobutoxy-thiophosphorylsulfanyl)-2-methylpropionic acid | | |
| Molecular Formula | C12 H25 O4 P1 S2 | Molecular weight (g/mole) | 328.42 |

13 Physical-chemical properties

EPI MPBPVP

| Melting Point (deg C) | 69.5 | Melting Point Experimental (deg C) | |
|-------------------------|-----------|--|---------|
| Boiling Point (deg C) | 395.64 | Boiling Point Experimental (deg C) | |
| Vapour Pressure (mm Hg) | 4.04E-006 | Vapour Pressure Experimental (mm Hg) | |
| Vapour Pressure (Pa) | 0.0005386 | Vapour pressure Subcooled Liquid (Pa) | 0.00141 |

EPI HENRYWIN

| HLC Bond Method (atm- m3/mole) | 4.54E-009 | HLC Group Method (atm- m3/mole) | |
|---------------------------------------|------------|--|-------|
| HLC Via VP/WSol (atm- m3/mole) | 9.965E-007 | HLC Via VP/WSol (Pa- m3/mole) | 0.101 |
| Henrys Law Const. Exp db (Pa-m3/mole) | | Henrys Law Const. Exp db (atm-m3/mole) | |

HLC: Henry's Law Constant

EPI WSKOW, WATERNT and HYDROWIN

| Water solubility from Kow (mg/L) | 1.752 | Water solubility from Fragments (mg/L) | 19.028 |
|----------------------------------|-------|---|--------|
| Water solubility Exp (mg/L) | | Water solubility Exp Ref | |
| Hydrolysis Ka half-life pH 7 | | Hydrolysis Kb half-life pH 7 | |
| | | | |
| Hydrolysis Ka half-life pH 8 | | Hydrolysis Kb half-life pH 8 | |
| Log Kow | 4.77 | | |
| Log Kow Exp | | Log Kow Exp Ref | |

LogKow: log octanol-water partition coefficient

ACDLabs

| pKa Acid | 4.9 |
|--------------------------|------|
| - Standard deviation (±) | 0.4 |
| pKa Base | -999 |
| - Standard deviation (±) | 0 |

pKa estimate 999: no acidic moiety found. pKa estimate -999: no basic moiety found.

14 Environment

15 Partition coefficients

| ACDLabs, pH | 1 | 4 | 5 | 6 | 7 | 8 | 9 |
|-------------|------|------|------|------|------|------|------|
| LogD | 4.04 | 3.99 | 3.68 | 2.91 | 1.94 | 0.98 | 0.24 |

EPI KOAWIN

| Log Koa | 11.501 | Log Kaw | -6.731 | |
|---------|--------|---------|--------|--|

Koa: octanol-air partition coefficient. Kaw: air-water partition coefficient

EPI AEROWIN

| Kp (m3/ug) Mackay-based | 0.00212 | Kp (m3/ug) Koa-based | 0.0778 |
|-------------------------|---------|----------------------|--------|
| Phi Junge-Pankow-based | 0.0712 | Phi Mackay-based | 0.145 |
| Phi Koa-based | 0.862 | | |

Kp: particle-gas partition coefficient. Phi: fraction of substance sorbed to atmospheric particulates

EPI KOCWIN

| Koc from MCI (L/kg) | 213.6 | Log Koc from MCI | 2.3296 |
|---------------------|-------|------------------|--------|
| Koc from Kow (L/kg) | 504 | Log Koc from Kow | 2.7024 |

Koc: soil adsorption coefficient of organic compounds. Kow: octanol-water partition coefficient. MCI: first order Molecular Connectivity Index

16 Level III Fugacity Environmental Partitioning

| EPI Level III Fugacity Model | Air | Water | Soil | Sediment |
|------------------------------|--------|-------|------|----------|
| Mass Amount (%) | 0.0606 | 20.3 | 79.4 | 0.203 |
| Half-Life (hr) | 1.95 | 360 | 720 | 3240 |
| Emissions (kg/hr) | 1000 | 1000 | 1000 | 0 |

Persistence time (hr): 633

Persistence time (days): 26.375

17 Sewage Treatment Plant (STP) overall chemical mass balance using 10,000 hr

| EPI STPWIN | Total removal | Biodegradation | Sludge Adsorption | Volatilization |
|------------|---------------|----------------|-------------------|----------------|
| (%) | 69.1 | 0.62 | 68.48 | 0 |

18 Atmospheric oxidation (25 deg C)

| EPI AOPWIN | ОН | Ozone |
|---|----------|-------|
| Half-Life (d) | 0.08129 | 0 |
| Half-Life (hr) | 0.976 | |
| Overall Rate Const. (OH: E-12 cm3/molecule-sec and OZ: E-17 cm3/molecule-sec) | 131.5709 | |

19 Biodegradation

EPI BIOWIN

| Biowin1 (linear model) Probability of Rapid Biodegradation | 0.9778 |
|--|--------|
| Biowin2 (non-linear model) Probability of Rapid Biodegradation | 1 |
| Biowin3 Expert Survey Ultimate Biodegradation | 2.9917 |
| Biowin3 Expert Survey Ultimate Timeframe | weeks |
| Biowin4 Expert Survey Primary Biodegradation | 4.2248 |
| Biowin4 Exp. Survey Primary Timeframe | days |
| Biowin5 (MITI linear model) Biodegradation Probability | 0.0692 |
| Biowin6 (MITI non-linear model) Biodegradation Probability | 0.0265 |
| Biowin7 (Anaerobic Linear) Biodegradation Probability | 0.7324 |
| Petroleum Hydrocarbon Biodegradation Half-Life (days) | |

Biowin1 and Biowin2: ≥0.5: "Rapid" <0.5: "Slow"
Biowin3 and Biowin4: 5 ~ hours; 4 ~ days; 3 ~ weeks; 2 ~ months; 1 ~ years.
Biowin5 and Biowin6: ≥0.5: "Readily", <0.5: "Not readily".
Biowin7: ≥0.5: "Fast", <0.5: "Slow"

| DK | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|--|-----|---------|------------|-----------|---------|
| Not Ready Biodegradability (POS=Not Ready) | | INC_OUT | INC_OUT | POS_OUT | NEG_OUT |

20 Bioaccumulation

EPI BCFBAF

| BCF (L/kg wet-wt) | 3.162 |
|---|-------|
| Log BCF (L/kg wet-wt) | 0.5 |
| Whole Body Primary Biotransformation Fish Half-Life (days) | 2.449 |
| BCF Arnot-Gobas (upper trophic) Including Biotransformation (L/kg wet-wt) | 863.2 |
| BCF Arnot-Gobas (upper trophic) Zero Biotransformation (L/kg wet-wt) | 5205 |
| BAF Arnot-Gobas (upper trophic) Including Biotransformation (L/kg wet-wt) | 878.6 |
| BAF Arnot-Gobas (upper trophic) Zero Biotransformation (L/kg wet-wt) | 44100 |

BCF: Bioconcentration factor, BAF: Bioaccumulation factor

21 Aquatic toxicity

| DK | Exp | Battery | Leadscope | SciQSAR |
|---|-----|----------|-----------|----------|
| Fathead minnow 96h LC50 (mg/L) | | 6.819669 | 11.14704 | 2.492296 |
| Domain | | IN | IN | IN |
| Daphnia magna 48h EC50 (mg/L) | | 1.281434 | 1.352996 | 1.209872 |
| Domain | | IN | IN | IN |
| Pseudokirchneriella s. 72h EC50 (mg/L) | | 33.57108 | 63.4994 | 3.642752 |
| Domain | | IN | IN | IN |

| EPI ECOSAR | Fish 96h | Daphnid 48h | Green Algae 96h |
|---|--------------------------------|--------------------------------|------------------------|
| LC50 (Fish) or EC50 (Daphnid and Algae) for Most Toxic Class (mg/L) | 0.8 | 0 | 1.382 |
| Max. Log Kow for Most Toxic Class | 5 | 5 | 6.4 |
| Most Toxic Class | Esters, Dithiophosphates-ac | Esters, Dithiophosphates-ac | Neutral Organic SAR |
| Note | | | |

ECOSAR Classes: Esters, Dithiophosphates-acid

22 ADME

23 Oral absorption

Equation from literature

| Lipinski's Rule-of-five score (bioavailability) | 0 |
|---|-----|
| Absorption from gastrointestinal tract for 1 mg dose (%) | 100 |
| Absorption from gastrointestinal tract for 1000 mg dose (%) | 90 |

Lipinski scores of 0 or 1: the substance may be bioavailable. Lipinski scores of 2, 3 or 4: the substance may not be bioavailable.

24 Skin absorption

EPI DERMWIN

| Dermal absorption (mg/cm2/event) | 0.000334 | |
|----------------------------------|----------|--|
| | | |

25 Distribution

Equation from literature

| Log brain/blood partition coefficient | 0.4604 |
|---------------------------------------|-----------|
| 9 | 1 1 1 2 1 |

Partitioning between the two tissues at equilibrium. >1: high, >0 to <1: medium, >-1 to <0, fair, <-1: low.

26 Metabolism

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|---|-----|---------|------------|-----------|---------|
| CYP2C9 substrates (Human clinical data) | | NEG_IN | NEG_IN | INC_OUT | NEG_IN |
| CYP2D6 substrates (Human clinical data) | | NEG_IN | NEG_OUT | NEG_IN | NEG_IN |

27 Human Health

28 Acute toxicity in Rodents

| ACDLabs | LD50 (mg/kg/d) | Reliability Index |
|-----------------------|----------------|-------------------|
| Rat Oral | 580 | 0.42 |
| Rat Intraperitoneal | 41.88 | 0.5 |
| Mouse Oral | 82.02 | 0.53 |
| Mouse Intraperitoneal | 100 | 0.1 |
| Mouse Intravenous | 290 | 0.6 |
| Mouse Subcutaneous | 440 | 0.29 |

Reliability index: <0.3 = Not reliable prediction quality; 0.3-0.5 = borderline prediction quality; 0.5-0.75 = moderate prediction quality; >0.75 = high prediction quality.

29 MRDD in Humans

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|--------------------------------------|-----|---------|------------|-----------|---------|
| MRDD in Humans ≤ 2.69 mg/kg- bw/d | | NEG_OUT | INC_OUT | NEG_IN | STR_OUT |

Model based on data on pharmaceuticals. Maximum recommended daily dose in pharmaceutical clinical trials employing primarily oral route of exposure and daily treatments, usually for 3-12 months.

30 Irritation and Sensitisation

| | Ехр | Battery | CASE Ultra | Leadscope | SciQSAR |
|---|-----|---------|------------|-----------|---------|
| Severe Skin Irritation in Rabbit | | NEG_OUT | NEG_OUT | POS_OUT | NEG_IN |
| Allergic Contact Dermatitis in Guinea Pig and Human | NA | INC_OUT | INC_OUT | NEG_OUT | INC_OUT |
| Respiratory Sensitisation in Humans | | INC_OUT | INC_OUT | INC_OUT | NEG_OUT |

31 Endocrine and Molecular Endpoints

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|---|-----|---------|------------|-----------|----------|
| Estrogen Receptor α Binding, Full training set (Human <i>in vitro</i>) | | INC_OUT | NEG_OUT | NEG_IN | POS_IN |
| Estrogen Receptor α Binding, Balanced Training Set (Human <i>in vitro</i>) | | NEG_OUT | NEG_OUT | INC_OUT | NEG_IN |
| Estrogen Receptor α Activation (Human <i>in vitro</i>) | | INC_OUT | NEG_OUT | NEG_OUT | NEG_OUT |
| Androgen Receptor Antagonism (Human <i>in vitro</i>) | | NEG_IN | NEG_IN | NEG_IN | NEG_IN |
| Thyroperoxidase (TPO) inhibition QSAR1 (Rat <i>in vitro</i>) | | NA | NA | NEG_OUT | NA |
| Thyroperoxidase (TPO) inhibition QSAR2 (Rat <i>in vitro</i>) | | NA | NA | NEG_OUT | NA |
| Thyroid Receptor α Binding (Human <i>in vitro</i>) (mg/L) | | | 52532.69 | 1077.853 | 429.1702 |
| Domain | | OUT | OUT | OUT | OUT |
| Thyroid Receptor β Binding (Human <i>in vitro</i>) (mg/L) | | | 10627.47 | 28.96341 | 62.63681 |
| Domain | | OUT | OUT | OUT | OUT |
| Pregnane X Receptor (PXR) Binding (Human <i>in vitro</i>) | NA | NEG_IN | NEG_IN | NEG_IN | NEG_IN |

32 Developmental Toxicity

| | Battery | CASE Ultra | Leadscope | SciQSAR |
|---------------------------------|---------|------------|-----------|---------|
| Teratogenic Potential in Humans | NEG_IN | INC_OUT | NEG_IN | NEG_IN |

33 Genotoxicity

34 Ashby Structural Alerts for DNA Reactivity

| | Battery | CASE Ultra | Leadscope | SciQSAR |
|-------------------------|---------|------------|-----------|---------|
| Ashby Structural Alerts | INC_OUT | POS_OUT | POS_IN | NEG_IN |

35 Bacterial Reverse Mutation Test (Ames test)

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|--|-----|---------|------------|-----------|---------|
| Ames test in S. typhimurium (in vitro) | | NEG_IN | NEG_IN | NEG_IN | INC_OUT |
| - Direct Acting Mutagens (without S9) | NA | INC_OUT | POS_OUT | INC_OUT | INC_OUT |
| - Base-Pair Ames Mutagens | NA | NEG_OUT | INC_OUT | INC_OUT | NEG_IN |
| - Frameshift Ames Mutagens | NA | NEG_IN | NEG_OUT | NEG_IN | NEG_IN |
| - Potent Ames Mutagens, Reversions ≥ 10 Times Controls | NA | INC_OUT | POS_OUT | POS_IN | NEG_IN |

For the four Ames "submodels" (Direct Acting Mutagens (without S9), Base-Pair Ames Mutagens, Frameshift Ames Mutagens, Potent Ames Mutagens) only use the predictions if the main Ames model (Ames test in S. typhimurium (*in vitro*)) is POS_IN.

36 Other in vitro Genotoxicity Endpoints

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|--|-----|---------|------------|-----------|---------|
| Chromosome Aberrations in Chinese Hamster Ovary (CHO) Cells | NA | NEG_IN | INC_OUT | NEG_IN | NEG_IN |
| Chromosome Aberrations in Chinese Hamster Lung (CHL) Cells | | NEG_OUT | NEG_OUT | NEG_IN | NEG_OUT |
| Mutations in Thymidine Kinase Locus in Mouse Lymphoma Cells | | NEG_IN | NEG_IN | NEG_IN | INC_OUT |
| Mutations in HGPRT Locus in Chinese Hamster Ovary (CHO) Cells | | NEG_IN | INC_OUT | NEG_IN | NEG_IN |
| Unscheduled DNA Synthesis (UDS) in Rat Hepatocytes | | NEG_IN | INC_OUT | NEG_IN | NEG_IN |
| Syrian Hamster Embryo (SHE) Cell Transformation | | INC_OUT | INC_OUT | NEG_IN | POS_IN |

HGPRT: Hypoxanthine-guanine phosphoribosyltransferase

37 In vivo Genotoxicity Endpoints

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|--|-----|---------|------------|-----------|---------|
| Sex-Linked Recessive Lethal (SLRL) Test in Drosophila m. | | INC_OUT | NEG_OUT | POS_IN | NEG_IN |
| Micronucleus Test in Mouse Erythrocytes | | NEG_IN | NEG_IN | NEG_IN | INC_OUT |
| Dominant Lethal Mutations in Rodents | | POS_OUT | INC_OUT | INC_OUT | POS_IN |
| Sister Chromatid Exchange in Mouse Bone Marrow Cells | | NEG_IN | INC_OUT | NEG_IN | NEG_IN |
| Comet Assay in Mouse | | POS_IN | POS_IN | NEG_IN | POS_IN |

38 Carcinogenicity

| | CASE Ultra | Leadscope |
|-----------------------------|------------|-----------|
| FDA RCA Cancer Male Rat | NEG_IN | NEG_IN |
| FDA RCA Cancer Female Rat | NEG_IN | NEG_IN |
| FDA RCA Cancer Rat | NEG_IN | NEG_IN |
| FDA RCA Cancer Male Mouse | NEG_IN | NEG_IN |
| FDA RCA Cancer Female Mouse | NEG_IN | NEG_IN |
| FDA RCA Cancer Mouse | NEG_IN | NEG_IN |
| FDA RCA Cancer Rodent | NEG_IN | NEG_OUT |

FDA RCA: Data from US Food and Drug Administration as part of Research Cooperation Agreement

| | Exp | Battery | CASE Ultra | Leadscope | SciQSAR |
|---------------------------------------|-----|---------|------------|-----------|---------|
| Liver Specific Cancer in Rat or Mouse | | INC_OUT | POS_OUT | NEG_IN | POS_IN |

| Abbreviations |
|--|
| INC: inconclusive. A definite call within the defined applicability domain could not be made. |
| NEG: negative |
| POS: positive |
| IN: inside applicability domain |
| OUT: outside applicability domain |
| Exp: Experimental values, from EpiSuite experimental databases or DK DTU QSAR models training sets. |
| NA: Not applicable, because training set data cannot be released for commercial models. |
| |
| Important notes |
| This is an automatically generated report from the Danish (Q)SAR Database, http://qsar.food.dtu.dk . |
| For predictions from CASE Ultra, Leadscope, SciQSAR as well as the Acute toxicity in rodent from ACDLabs information on the software versions can be found in the QMRFs. For the other predicted properties the software versions are: |
| EPI MPBPWIN v1.43 |
| EPI HENRYWIN v3.20 |
| EPI WSKOW v1.42 |
| EPI WATERNT v1.01 |
| EPI KOAWIN v1.10 |
| EPI AEROWIN v1.00 |
| EPI KOCWIN v2.00 |
| EPI Level III Fugacity Model (EPI Suite v4.11) |
| EPI STPWIN (EPI Suite v4.11) |
| EPI AOPWIN v1.92 |
| EPI BIOWIN v4.10 |
| EPI BCFBAF v3.01 |
| EPI ECOSAR v1.11 |
| EPI DERMWIN v2.02 |

ACD/ ToxSuite 2.95.1 Ionization\pKa

ACD/ ToxSuite 2.95.1

It is recommended to run the latest version of the EPI Suite Programs in preference of the predictions given in this document when these endpoints are of importance and new versions have been released from the United States Environmental Protection Agency in comparisons. EPI Suite can be downloaded from the US EPA homepage: http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm

For further information on the applied systems, see the following homepages:

CASE Ultra: http://www.multicase.com/case-ultra

Leadscope: http://www.leadscope.com/

SciQSAR: http://lhasa-llc.com/

ToxSuite: http://www.acdlabs.com/

Copyright notice, terms and conditions of use

Permission is granted to use information from the database as is. The database is an expert tool where the final assessment of properties is not dictated by the (Q)SAR estimates, but by the user's own scientific judgment. Aside from the fact that models are never perfect, the (Q)SAR field is under rapid development and models are regularly updated and improved. It is also impossible to provide the detailed information accompanying each individual prediction that is available to those who do not own licences to the software platforms. The structural information in the database stems from many sources and in some cases it may be wrong. The structures are also in some cases abbreviated in that possible anions and cations have been removed. This can have important toxicological significance (e.g. for Heavy Metal salts).

All access to the database should happen through the provided client-side software and without any use of automated workflow or scripting.

Reproduction of information from the database is permitted provided the source is acknowledged as follows: "Danish (Q)SAR Database, Division of Diet, Disease Prevention and Toxicology, National Food Institute, Technical University of Denmark, http://qsar.food.dtu.dk."

The Technical University of Denmark (DTU) is not responsible for any errors or inaccuracies the database may contain and is not liable for any use that may be made of the information contained therein. DTU do not warrant, and hereby disclaim any warranties, with respect to the accuracy, adequacy or completeness of any information obtained from this database. Nor do we warrant that the site will operate in an uninterrupted or error-free manner or that the site and its components are free of viruses or other harmful components. Use of information obtained from or through this site is at your own risk. As a user of this database, you agree to indemnify and hold DTU harmless from any claims, losses or damages, including legal fees, resulting from your use of this database, and to fully cooperate in DTU's defense against any such claims.

The user requests are processed by the server hosting the database which in the process stores information. Only authorized employees have authorized access to the server and reasonable measures are in place to protect the server from unauthorized access. DTU uses the stored user request information solely for error tracking and to collect anonymized statistics (number of users, number of searches, number of report downloads etc.), and we do not release any information at the level of individual searches. However, as the online user access to the database does not happen through a secure connection and as any server/PC/network that the requests pass through may be compromised by unauthorized access, we cannot guarantee that the information submitted by users does not fall into the hands of third parties.

These terms are governed by Danish Law, with the exception of international private law and conflict of law rules, to the extent that such rules would result in the application of another country's law. Any dispute arising between the parties in connection with the use of this database, including the interpretation of the above terms, which cannot be settled amicably by negotiation between the parties, shall be settled by the Court of Lyngby, Denmark, as the court of first instance.